

Ben Connell Laura Downie Tim Martin

CASE STUDIES

## Ben Connell Laura Downie Tim Martin

casestudies

## Learning objectives

• To appreciate the value of clinical audit

• To understand current clinical evidence relating to blue light-filtering products

• To be able to manage corneal infiltrates and keratitis more confidently



## Q1 - Cataract surgery: % of patients with 2 lines loss BCVA?



Start the presentation to see live content. Still no live content? Install the app or get help at PollEv.com/app



## Problem

- Doctors don't know their results
  - Areas of inadequacy?
  - Improving?
  - Could perform better?





## Vision

A culture where health professionals:

- Know their results/ outcomes
- Take pride in their accuracy
  - Incentivised to do better by
    - Data obtained insights
    - Reflection and peer interaction

#### Different approaches:

- 1. <u>Surgeon scorecard</u>
- 2. Airline pilot model

## Technique

🐄 You have Test, Test1's medical notes locked. Medicare Kiosk 🕗 🗔 (dosed)

#### Data input/extraction from EMR (Best/2 faction)

#### 12 surgeon users

#### ~7000 cases, 20 years

#### Results



STAT

## Development



## Some thoughts and questions

- Strong surgeon motivation
- Interesting insights
  - Patients with worse vison
  - Risk factors for worse vision
- Control for case mix/co-morbidities



Questions

- 1. Should surgeons have to audit their performance?
- 2. If so, which model:
- a) Results kept private
- b) Results kept public
- 3. Should optometrists have to audit their performance?
  - a) Should *all* optometrists have to audit their performance (should their be exceptions)?
  - b) Should their results be made public?

# Blue-light filtering spectacle and intraocular lenses

### Case scenario

Brian, a 40-year old accountant, attends for an eye test.

- Performs several hours of computer work daily
- Recently noticing increased levels of eye strain.

No significant ocular health findings. His mother has AMD.

You recommend a pair of SVN glasses.

Brian mentions that his work colleague recently bought some new glasses with a 'blue-block coating'.

He asks whether you would recommend that he has this feature on his new glasses.



# Would you recommend blue light-filtering spectacle lenses to Brian?



No

Start the presentation to see live content. Still no live content? Install the app or get help at PollEv.com/app

## Which of the following statements BEST describes your overall position on blue light-filtering spectacle lenses?

They act as a general safety measure to protect the eyes from the effects of blue light.

They are useful for reducing eye strain from digital device use.

They are not clinically justified.

I am not aware of these lenses.

## Blue light



#### Adverse effects?

- Retinal damage<sup>1-3</sup>
- Digital eye strain<sup>4</sup>
- Alterations to sleep cycle<sup>5</sup>

Noell et al., Invest Ophthalmol (1966).
 Ruffolo et al., Invest Ophthalmol (1978).
 Tejedor et al., PLoS ONE (2018
 American Academy of Optometry (1995)
 Dijk et al., PLoS Biol (2009)

Smick et al. Report of a roundtable sponsored by Essilor of America (2013)



## Sources emitting blue light

- Sun
- Incandescent light
- Fluorescent light
- Light emitting diode
- Liquid crystal display
- Mobile phones
- Tablets

Eye (2016) 30, 230–233 © 2016 Macmillan Publishers Limited All rights reserved 0950-222X/16 www.nature.com/eye

> Low-energy light bulbs, computers, tablets and the blue light hazard



Image sources: http://www.eyepromise.com/doctors/eye-health/bluelight-protection/

Type of screens	Blue light weighted radiance, W m <sup>-2</sup> sr <sup>-1</sup>	Hazard ratio W lm <sup>-1</sup>
Computer	0.08	8.17 x 10 <sup>-4</sup>
Laptop	0.11	8.16 x 10 <sup>-4</sup>
Tablet	0.13	8.73 x 10 <sup>-4</sup>
Smartphones	0.26	8.90 x 10 <sup>-4</sup>
Exposure limit for long term viewing (International standards)		100 W m <sup>-2</sup> sr <sup>-1</sup>



1300 221 488		Contact us	💄 🗳 Cart
		Search	٩
Home Shop ∽ Le	arn 🗸 Testimon	ials Our Story	Gift of Vision

#### blue light exposure and digital eye strain - the vision council



day interactions with our

environment easier and safe. Although there are many positive Designer Frames



eye strain



## Blue light 'protection'



**DuraVision® BlueProtect by ZEISS** The ZEISS Blue-Violet Light Blocking Solutions.









#### Anti Blue Light Screen Protector



## What percentage of blue light do you think blue-blocking spectacle lenses typically filter?

15%30% 50% 67%

### Link between blue light and retinal damage?



## Do you think daily environmental exposure to blue light can cause retinal damage?



## **Clinical evidence**



**OPHTHALMIC & PHYSIOLOGICAL OPTICS** THE JOURNAL OF THE COLLEGE OF OPTOMETRISTS



Ophthalmic & Physiological Optics ISSN 0275-5408

#### The effect of blue-light blocking spectacle lenses on visual performance, macular health and the sleep-wake cycle: a systematic review of the literature

John G Lawrenson<sup>1</sup> (b), Christopher C Hull<sup>1</sup> (b) and Laura E Downie<sup>2</sup> (b)

<sup>1</sup>Centre for Applied Vision Research, Division of Optometry and Visual Science, City University of London, London, UK, and <sup>2</sup>Department of Optometry and Vision Sciences, The University of Melbourne, Melbourne, Victoria, Australia

*Conclusions:* We find a lack of high quality evidence to support using BB spectacle lenses for the general population to improve visual performance or sleep quality, alleviate eye fatigue or conserve macular health.

## **Clinical evidence**



May 2018



**Cochrane** Database of Systematic Reviews

Blue-light filtering intraocular lenses (IOLs) for protecting macular health (Review)

Downie LE, Busija L, Keller PR

#### JAMA Ophthalmology | Special Communication

Analysis of a Systematic Review About Blue Light-Filtering Intraocular Lenses for Retinal Protection Understanding the Limitations of the Evidence

Laura E. Downie, BOptom, PhD(Melb); Richard Wormald, FRCS, FRCOphth; Jennifer Evans, MSc, PhD; Gianni Virgili, MD; Peter R. Keller, BAppSc(Optom), PhD; John G. Lawrenson, FCOptom, PhD; Tianjing Li, MD, MHS, PhD

#### Jan 2019

#### **Results:**

- 51 RCTs from 17 countries
- Clinical outcomes in >5000 eyes
- Follow-up: 1 month to 5 years (most studies: 3 months)

#### Major clinical finding - Primary outcome:

*"Moderate certainty for no clinically meaningful difference* (MD -0.01 logMAR, 95% CI 0.03 lower to 0.02 higher; *p*=0.48) in *short-term BCVA* between the two IOL types."



#### <u>Footnotes</u>

(1) Reported at 12 months postoperatively, as the mean of right and left eyes, combining two groups with blue-light filtering IOLs (n=23/group) and two groups with non-blue-light filtering IOLs (n = ... (2) Reported at six months postoperatively

"... the use of blue-light filtering IOLs to impart benefits to macular health is not currently supported by the best-available evidence."

# What, if any, do you consider the MOST important potential 'harm' of prescribing a blue-light filtering lens?

There aren't any harms.

Cosmetic appearance of the lenses.

Additional cost to patients when there is evidence for no clinical benefit.

Effects on colour vision.

## Contemporary Australian: UV filtering IOLs

- Alcon: dominant IOL
  - Exclusively blue blocking
- 2<sup>nd</sup> and 3<sup>rd</sup> leading manufactures: clear
   Zeiss
  - Zelss
  - Johnson and Johnson
- Smaller manufacturers
  - Offer both (Hoya, MBI)
- Surgeon choice driven by other factors
  - Company support
  - Toric rotational stability
  - Material marking
  - Cost
  - Plate haptic preference



## Now, would you recommend blue light-filtering spectacle lenses to Brian?



No

Start the presentation to see live content. Still no live content? Install the app or get help at PollEv.com/app

#### **BOOTS OPTICIANS FINED £40,000 OVER MISLEADING BLUE LIGHT ADVERTISING**

The General Optical Council has sanctioned the multiple for unsubstantiated claims about blue light filtering lenses

26 May 2017 by Selina Powell

Category: High Street, Multiple, GOC, Professional conduct

The General Optical Council (GOC) has reprimanded Boots Opticians with a £40,000 fine for a "misleading" advertisement about Boots Protect Plus Blue (BPPB) lenses.

In a decision published today (26 May), the optical regulator found that there was potential for patients to be misled by the multiple overstating claims about blue light and the benefits of its BPPB lenses in an advertisement that was published in *The Times* in January 2015.

The Advertising Standards Authority (ASA) received complaints about the content of the advertisement, including claims that blue light from LED TVs, smartphones and energy saving light bulbs caused damage to retinal cells over time, and that BPPB lenses protected against blue light from these sources. The authority found that these claims were misleading and unsubstantiated.

A later BBC *Watchdog* investigation found that some Boots Opticians practices were continuing to make misleading claims about the lenses, including through in-store leaflets.

## Panel discussion

### Spectacle lenses

- @TM: Do you think placebo effects play a role in subjective responses to these lens products?
- @TM: How frequently are patients presenting with knowledge of these products and requesting them?

### IOLs

 
 — @BC: Is it typical to discuss the choice of IOL (i.e., blue-light filtering versus UV-filtering) with patients prior to surgery? Why/why not?

## Corneal infiltrates



#### 23 yo F

2 weeks ago eye was red & irritated, improved. Continued wearing mini-scleral CLs.

Mild yellow discharge on CL, nil noted otherwise Pain "13/10"

#### POH:

- Mini-scleral CL wearer due to bilateral advanced KCN Dx 2016
- Bilateral CXL 2018
- History of not attending scheduled CL reviews

GH: Unremarkable apart from mild asthma & hay fever





23 yo F

PC:

2 weeks ago eye was red & irritated, improved. Continued wearing mini-scleral CLs.

Trace yellow discharge on CL, nil noted otherwise

Pain 13/10

#### POH:

- Mini-scleral CL wearer due to bilateral advanced KCN Dx 2016
- Bilateral CXL 2018
- History of not attending scheduled CL reviews

GH: Unremarkable apart from mild asthma & hay fever



Pain	++++(+)
Epithelial defect	+
Discharge	+
Anterior chamber	-
Location	Peripheral
Size (above or below 2mm)	<2mm

Chlorsig qid & Flarex qid

Ciloxan q2h

Ciloxan q15mins for 6 hours, then q1h

Ciloxan q2h & Flarex qid Refer to an ophthalmologist for assessment +/- corneal scrape



## **Incidence of CL related MK**

Table 2 Annual incidence of contact lens-related bacterial, fungal, and protozoan keratitis

Lens type	Bacterial	Fungal	Acanthamoeba
Overall incidence	4%/10,000	~1/50,000 <sup>119,a</sup>	I-33/million <sup>35</sup>
Soft lenses (daily wear)	1.99–4.18/10,000	NR	NR
Soft lenses (extended wear)	19.5%10,000	NR	NR
Hydrogel	9.310-20.98/10,000	NR	NR
Silicone hydrogel	20.914-25.49/10,000	NR	NR
Gas-permeable (daily wear)	0.810-4.08/10,000	NR	NR
Orthokeratology	7.718/10,000	NR	NR

**Note:** <sup>a</sup>Estimation calculated from Konda et al<sup>119</sup> which stated 5% of all contact lens microbial keratitis is fungal. **Abbreviation:** NR, not reported.

#### What about mini-sclerals?



### 20 yo F

L eye puffy/red for 3 days. Swollen superior lid. Can't open eye.

Was wearing CL's at time, has ceased since.

Pain 4/10 when closed, unable to judge when open. Tearing a lot.

#### **GH: Healthy**

POH: CL - 2 weekly, unknown solution, cleans on removal, throws away at end of fortnight, no shower/swim/sleep.

VA R: 6/7.5 & L 6/9.5 (PH 6/7.5)





### 20 yo F

L eye puffy/red for 3 days. Swollen superior lid. Can't open eye.

Was wearing CL's at time, has ceased since.

Pain 4/10 when closed, unable to judge when open. Tearing a lot.

#### **GH: Healthy**

POH: CL - 2 weekly, unknown solution, cleans on removal, throws away at end of fortnight, no shower/swim/sleep.

• VA R: 6/7.5 & L 6/9.5 (PH 6/7.5)



Pain	+++
Epithelial defect	+
Discharge	+++
Anterior chamber	-
Location	Peripheral
Size (above or below 2mm)	>2mm





Pain	+++	
Epithelial defect	+	
Discharge	+++	
Anterior chamber	Faint hypopyon started to form	
Location	Peripheral	
Size (above or below 2mm)	>2mm	

# If a corneal culture is attempted, approximately how likely is a positive result?

90% 70% 50% 30%

Start the presentation to see live content. Still no live content? Install the app or get help at PollEv.com/app

Am J Ophthalmol. 2007 June ; 143(6): 940-944.

#### The Clinical Diagnosis of Microbial Keratitis

Matthew A. Dahlgren, MD, Ahila Lingappan, MD, and Kirk R. Wilhelmus, MD, PhD From the Department of Ophthalmology, Baylor College of Medicine, Houston, Texas. Dr. Dahlgren is currently with Milwaukee Eye Care Associates, Milwaukee, Wisconsin.

#### Abstract

**Purpose**— To evaluate the ability of ophthalmologists to predict the laboratory results of presumed microbial keratitis and to explore which findings might influence diagnostic prognostication.

Design—Prospective cross-sectional study.

**Methods**— Fifteen ophthalmologists completed study forms at the initial presentation of patients with presumed microbial keratitis. After predicting the category of microbial recovery, clinicians submitted corneal scrapings for masked laboratory processing. The relative effects of ocular inflammatory signs on correct microbial diagnosis were explored with Poisson regression.

**Results**— Clinical examiners correctly predicted the presence or absence of microbial recovery in 79 (76%) of 104 ulcerative keratitis and successfully distinguished among bacterial, fungal, and amoebic keratitis for 54 (73%) of 74 culture-positive infections, although only 31 (42%) were properly subcategorized. The positive predictive value of clinical diagnosis was 65% (95% confidence interval (CI), 43%–84%) for 20 eyes with *Pseudomonas* keratitis, 48% (95% CI, 32%–63%) for 38 other bacterial keratitis, 45% (95% CI, 17%–77%) for 13 fungal keratitis, and 89% (95% CI, 52%–100%) for nine *Acanthamoeba* keratitis. The recognition of *Pseudomonas* keratitis was significantly improved by the occurrence of a larger infiltrate (P = .02), and correctly predicting *Acanthamoeba* keratitis was enhanced by observing a ring infiltrate (P < .001). Antimicrobial use before referral significantly attenuated clinical diagnosis (P = 0.03) and hampered microbial recovery (P = 0.004).

To culture, or not to culture?









#### Case 1

Since increased use of mini-sclerals & Ortho K has there been an increase?

- Inflammatory events?
- MK?

How would you deal with the unreliable patient/serial no show? Does this change your management plan?

- @LD: Have you refused CL fitting to patients with poor track record?
- @BC & LD: Would you change your therapeutic care?

#### Case 2

**Empirical treatment** 

• @BC: In your experience does prior empirical treatment lead to poorer outcomes?